1
|
da Silva EG, Borges Dos Anjos LR, Mendes
de Lima R, Alves TB, Pedrino GR, Helena da Silva Cruz A, da Silva
Santos R, Freiria-Oliveira AH and da Silva Reis AA: Clinical data
and risk factors for diabetic nephropathy in Brazilian central
population. Data Brief. 21:1315–1320. 2018.PubMed/NCBI View Article : Google Scholar
|
2
|
Chai Z, Wu T, Dai A, Huynh P, Koentgen F,
Krippner G, Ren S and Cooper ME: Targeting the CDA1/CDA1BP1 Axis
Retards Renal Fibrosis in Experimental Diabetic Nephropathy.
Diabetes. 68:395–408. 2019.PubMed/NCBI View Article : Google Scholar
|
3
|
Du N, Xu Z, Gao M, Liu P, Sun B and Cao X:
Combination of Ginsenoside Rg1 and Astragaloside IV reduces
oxidative stress and inhibits TGF-β1/Smads signaling cascade on
renal fibrosis in rats with diabetic nephropathy. Drug Des Devel
Ther. 12:3517–3524. 2018.PubMed/NCBI View Article : Google Scholar
|
4
|
Qiu DD, Liu J, Shi JS, An Y, Ge YC, Zhou
ML and Jiang S: Renoprotection provided by dipeptidyl peptidase-4
inhibitors in combination with angiotensin receptor blockers in
patients with type 2 diabetic nephropathy. Chin Med J (Engl).
131:2658–2665. 2018.PubMed/NCBI View Article : Google Scholar
|
5
|
Chen F, Zhu X, Sun Z and Ma Y: Astilbin
inhibits high glucose-induced inflammation and extracellular matrix
accumulation by suppressing the TLR4/MyD88/NF-κB pathway in rat
glomerular mesangial cells. Front Pharmacol. 9(1187)2018.PubMed/NCBI View Article : Google Scholar
|
6
|
Rovira-Llopis S, Escribano-Lopez I,
Diaz-Morales N, Iannantuoni F, Lopez-Domenech S, Andújar I, Jover
A, Pantoja J, Pallardo LM, Bañuls C, et al: Downregulation of
miR-31 in diabetic nephropathy and its relationship with
inflammation. Cell Physiol Biochem. 50:1005–1014. 2018.PubMed/NCBI View Article : Google Scholar
|
7
|
Moreno JA, Gomez-Guerrero C, Mas S, Sanz
AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S and Egido J:
Targeting inflammation in diabetic nephropathy: A tale of hope.
Expert Opin Investig Drugs. 27:917–930. 2018.PubMed/NCBI View Article : Google Scholar
|
8
|
Li J, Dong R, Yu J, Yi S, Da J, Yu F and
Zha Y: Inhibitor of IGF1 receptor alleviates the inflammation
process in the diabetic kidney mouse model without activating
SOCS2. Drug Des Devel Ther. 12:2887–2896. 2018.PubMed/NCBI View Article : Google Scholar
|
9
|
Eriguchi M, Bernstein EA, Veiras LC, Khan
Z, Cao DY, Fuchs S, McDonough AA, Toblli JE, Gonzalez-Villalobos
RA, Bernstein KE, et al: The absence of the ACE N-domain decreases
renal inflammation and facilitates sodium excretion during diabetic
kidney disease. J Am Soc Nephrol. 29:2546–2561. 2018.PubMed/NCBI View Article : Google Scholar
|
10
|
Li J, Li N, Yan S, Liu M, Sun B, Lu Y and
Shao Y: Ursolic acid alleviates inflammation and against diabetes
induced nephropathy through TLR4 mediated inflammatory pathway. Mol
Med Rep. 18:4675–4681. 2018.PubMed/NCBI View Article : Google Scholar
|
11
|
Gurley SB, Ghosh S, Johnson SA, Azushima
K, Sakban RB, George SE, Maeda M, Meyer TW and Coffman TM:
Inflammation and Immunity Pathways Regulate Genetic Susceptibility
to Diabetic Nephropathy. Diabetes. 67:2096–2106. 2018.PubMed/NCBI View Article : Google Scholar
|
12
|
Olatunji OJ, Chen H and Zhou Y: Lycium
chinense leaves extract ameliorates diabetic nephropathy by
suppressing hyperglycemia mediated renal oxidative stress and
inflammation. Biomed Pharmacother. 102:1145–1151. 2018.PubMed/NCBI View Article : Google Scholar
|
13
|
Zhang X, Guo K, Feng X, Zhao X, Huang Z
and Niu JJBB: FGF23C-tail improves diabetic nephropathy
by attenuating renal fibrosis and inflammation. BMC Biotechnol.
18(33)2018.PubMed/NCBI View Article : Google Scholar
|
14
|
Chen X and Fang M: Oxidative stress
mediated mitochondrial damage plays roles in pathogenesis of
diabetic nephropathy rat. Eur Rev Med Pharmacol Sci. 22:5248–5254.
2018.PubMed/NCBI View Article : Google Scholar
|
15
|
Zhang B, Zhang X, Zhang C, Shen Q, Sun G
and Sun X: Notoginsenoside R1 protects db/db mice against diabetic
nephropathy via upregulation of Nrf2-mediated HO-1 expression.
Molecules. 24(24)2019.PubMed/NCBI View Article : Google Scholar
|
16
|
Liu CH, Hua N, Fu X, Pan YL, Li B and Li
XD: Metformin regulates atrial SK2 and SK3 expression through
inhibiting the PKC/ERK signaling pathway in type 2 diabetic rats.
BMC Cardiovasc Disord. 18(236)2018.PubMed/NCBI View Article : Google Scholar
|
17
|
Ashamalla M, Youssef I, Yacoub M,
Jayarangaiah A, Gupta N, Ray J, Iqbal S, Miller R, Singh J and
McFarlane SI: Obesity, Diabetes and Gastrointestinal Malignancy:
The role of Metformin and other Anti-diabetic Therapy. Glob J Obes
Diabetes Metab Syndr. 5:008–14. 2018.PubMed/NCBI View Article : Google Scholar
|
18
|
Liu Y, Hu X, Shan X, Chen K and Tang H:
Rosiglitazone metformin adduct inhibits hepatocellular carcinoma
proliferation via activation of AMPK/p21 pathway. Cancer Cell Int.
19(13)2019.PubMed/NCBI View Article : Google Scholar
|
19
|
Donnan K and Segar L: SGLT2 inhibitors and
metformin: Dual antihyperglycemic therapy and the risk of metabolic
acidosis in type 2 diabetes. Eur J Pharmacol. 846:23–29.
2019.PubMed/NCBI View Article : Google Scholar
|
20
|
Abdellatif M, Sedej S, Carmona-Gutierrez
D, Madeo F and Kroemer G: Autophagy in Cardiovascular Aging. Circ
Res. 123:803–824. 2018.PubMed/NCBI View Article : Google Scholar
|
21
|
Li DD, Guo JF, Huang JJ, Wang LL, Deng R,
Liu JN, Feng GK, Xiao DJ, Deng SZ, Zhang XS and Zhu XF:
Rhabdastrellic acid-A induced autophagy-associated cell death
through blocking Akt pathway in human cancer cells. PLoS One.
5(e12176)2010.PubMed/NCBI View Article : Google Scholar
|
22
|
DiTacchio KA, Heinemann SF and
Dziewczapolski G: Metformin treatment alters memory function in a
mouse model of Alzheimer's disease. J Alzheimers Dis. 44:43–48.
2015.PubMed/NCBI View Article : Google Scholar
|
23
|
Arnoux I, Willam M, Griesche N, Krummeich
J, Watari H, Offermann N, Weber S, Narayan Dey P, Chen C, Monteiro
O, et al: Metformin reverses early cortical network dysfunction and
behavior changes in Huntington's disease. eLife.
7(7)2018.PubMed/NCBI View Article : Google Scholar
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
25
|
Huang S, Xu Y, Ge X, Xu B, Peng W, Jiang
X, Shen L and Xia L: Long noncoding RNA NEAT1 accelerates the
proliferation and fibrosis in diabetic nephropathy through
activating Akt/mTOR signaling pathway. J Cell Physiol, 2018.
|
26
|
Kim H, Dusabimana T, Kim SR, Je J, Jeong
K, Kang MC, Cho KM, Kim HJ and Park SW: Supplementation of
abelmoschus manihot ameliorates diabetic nephropathy and hepatic
steatosis by activating autophagy in mice. Nutrients.
10(10)2018.PubMed/NCBI View Article : Google Scholar
|
27
|
Liu L, Yang L, Chang B, Zhang J, Guo Y and
Yang X: The protective effects of rapamycin on cell autophagy in
the renal tissues of rats with diabetic nephropathy via
mTOR-S6K1-LC3II signaling pathway. Ren Fail. 40:492–497.
2018.PubMed/NCBI View Article : Google Scholar
|
28
|
Hu ZB, Ma KL, Zhang Y, Wang GH, Liu L, Lu
J, Chen PP, Lu CC and Liu BC: Inflammation-activated CXCL16 pathway
contributes to tubulointerstitial injury in mouse diabetic
nephropathy. Acta Pharmacol Sin. 39:1022–1033. 2018.PubMed/NCBI View Article : Google Scholar
|
29
|
Cebeci E, Cakan C, Gursu M, Uzun S,
Karadag S, Koldas M, Calhan T, Helvaci SA and Ozturk S: The main
determinants of serum resistin level in type 2 diabetic patients
are renal function and inflammation not presence of microvascular
complication, Obesity and Insulin Resistance. Exp Clin Endocrinol
Diabetes. 127:189–194. 2019.PubMed/NCBI View Article : Google Scholar
|
30
|
Heidari A, Hamidi G, Soleimani A,
Aghadavod E and Asemi Z: Effects of coenzyme Q10 supplementation on
gene expressions related to insulin, lipid, and inflammation
pathways in patients with diabetic nephropathy. Iran J Kidney Dis.
12:14–21. 2018.PubMed/NCBI
|
31
|
Aroune D, Libdiri F, Leboucher S, Maouche
B, Marco S and El-Aoufi S: Changes in the NFκB and E-cadherin
expression are associated to diabetic nephropathy inPsammomys
obesus. Saudi J Biol Sci. 24:843–850. 2017.PubMed/NCBI View Article : Google Scholar
|
32
|
Jain SK, Croad JL, Velusamy T, Rains JL
and Bull R: Chromium dinicocysteinate supplementation can lower
blood glucose, CRP, MCP-1, ICAM-1, creatinine, apparently mediated
by elevated blood vitamin C and adiponectin and inhibition of
NFkappaB, Akt, and Glut-2 in livers of zucker diabetic fatty rats.
Mol Nutr Food Res. 54:1371–1380. 2010.PubMed/NCBI View Article : Google Scholar
|
33
|
Liu X, Zhang Y, Shi M, Wang Y, Zhang F,
Yan R, Liu L, Xiao Y and Guo B: Notch1 regulates PTEN expression to
exacerbate renal tubulointerstitial fibrosis in diabetic
nephropathy by inhibiting autophagy via interactions with Hes1.
Biochem Biophys Res Commun. 497:1110–1116. 2018.PubMed/NCBI View Article : Google Scholar
|
34
|
Zhang Y, Zhao S, Wu D, Liu X, Shi M, Wang
Y, Zhang F, Ding J, Xiao Y and Guo B: MicroRNA-22 promotes renal
tubulointerstitial fibrosis by targeting PTEN and suppressing
autophagy in diabetic nephropathy. J Diabetes Res.
2018(4728645)2018.PubMed/NCBI View Article : Google Scholar
|
35
|
Wang X, Gao L, Lin H, Song J, Wang J, Yin
Y, Zhao J, Xu X, Li Z and Li L: Mangiferin prevents diabetic
nephropathy progression and protects podocyte function via
autophagy in diabetic rat glomeruli. Eur J Pharmacol. 824:170–178.
2018.PubMed/NCBI View Article : Google Scholar
|
36
|
Feng Y, Chen S, Xu J, Zhu Q, Ye X, Ding D,
Yao W and Lu Y: Dysregulation of lncRNAs GM5524 and GM15645
involved in high glucose induced podocyte apoptosis and autophagy
in diabetic nephropathy. Mol Med Rep. 18:3657–3664. 2018.PubMed/NCBI View Article : Google Scholar
|
37
|
Pontrelli P, Oranger A, Barozzino M,
Divella C, Conserva F, Fiore MG, Rossi R, Papale M, Castellano G,
Simone S, et al: Deregulation of autophagy under hyperglycemic
conditions is dependent on increased lysine 63 ubiquitination: A
candidate mechanism in the progression of diabetic nephropathy. J
Mol Med (Berl). 96:645–659. 2018.PubMed/NCBI View Article : Google Scholar
|
38
|
Hou S, Zhang T, Li Y, Guo F and Jin X:
Glycyrrhizic acid prevents diabetic nephropathy by activating
AMPK/SIRT1/PGC-1α signaling in db/db Mice. J Diabetes Res.
2017(2865912)2017.PubMed/NCBI View Article : Google Scholar
|